Primary pulmonary histiocytic sarcoma in dogs

A retrospective analysis of 37 cases (2000-2015)

Katelyn W. Marlowe, Cecilia S. Robat, Dawn M. Clarke, Angela Taylor, Maude Touret, Brian D Husbands, David M. Vail

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Primary pulmonary histiocytic sarcoma (PHS) has been reported, but is not well characterized. The aim of this retrospective study was to describe clinical characteristics, characterize prognostic factors and report the outcome of a larger group of dogs with primary PHS. Medical records of dogs diagnosed with primary PHS at 11 institutions were retrospectively reviewed. Thirty-seven dogs were included; 13 received CCNU-based chemotherapy alone, 18 received surgery and adjuvant CCNU-based chemotherapy, 3 received medical management alone and 3 dogs received surgery alone. The overall median progression free survival (PFS) and the median survival (overall survival [OS]) were 197 and 237 days, respectively. Measurable responses were noted in dogs receiving only chemotherapy; however, responses were not durable with PFS (91 days) and OS times (131 days) shorter than overall medians. Dogs that received surgery and chemotherapy had significantly prolonged PFS (276 days, P = 0.001) and OS (374 days, P = 0.001), compared with dogs not receiving surgery. As only three dogs undergoing surgery did not receive chemotherapy, it is not possible to determine the contribution of chemotherapy as an adjuvant to surgery. Dogs without evidence of intra-thoracic metastatic disease were much more likely to undergo surgery (odds ratio = 7.04; P = 0.018). While the presence of metastasis or clinical signs at diagnosis negatively impacted PFS, only the former negatively impacted OS. These data imply that dogs presenting with PHS amenable to surgery (ie, no clinical evidence of metastasis) benefit from surgical intervention; however, the lack of a comparable surgery alone group precludes assessment of the efficacy of post-surgical adjuvant chemotherapy.

Original languageEnglish (US)
Pages (from-to)658-663
Number of pages6
JournalVeterinary and Comparative Oncology
Volume16
Issue number4
DOIs
StatePublished - Dec 1 2018

Fingerprint

Histiocytic Sarcoma
sarcoma
lungs
Dogs
surgery
drug therapy
Lung
dogs
Disease-Free Survival
Drug Therapy
Lomustine
adjuvants
Adjuvant Chemotherapy
metastasis
Thoracic Diseases
Neoplasm Metastasis
chest
retrospective studies
odds ratio
Medical Records

Keywords

  • dogs
  • histiocytic sarcoma
  • lung neoplasms
  • oncology

PubMed: MeSH publication types

  • Journal Article

Cite this

Primary pulmonary histiocytic sarcoma in dogs : A retrospective analysis of 37 cases (2000-2015). / Marlowe, Katelyn W.; Robat, Cecilia S.; Clarke, Dawn M.; Taylor, Angela; Touret, Maude; Husbands, Brian D; Vail, David M.

In: Veterinary and Comparative Oncology, Vol. 16, No. 4, 01.12.2018, p. 658-663.

Research output: Contribution to journalArticle

Marlowe, Katelyn W. ; Robat, Cecilia S. ; Clarke, Dawn M. ; Taylor, Angela ; Touret, Maude ; Husbands, Brian D ; Vail, David M. / Primary pulmonary histiocytic sarcoma in dogs : A retrospective analysis of 37 cases (2000-2015). In: Veterinary and Comparative Oncology. 2018 ; Vol. 16, No. 4. pp. 658-663.
@article{c11948b85bf24ed5a33b0bcbf9356c50,
title = "Primary pulmonary histiocytic sarcoma in dogs: A retrospective analysis of 37 cases (2000-2015)",
abstract = "Primary pulmonary histiocytic sarcoma (PHS) has been reported, but is not well characterized. The aim of this retrospective study was to describe clinical characteristics, characterize prognostic factors and report the outcome of a larger group of dogs with primary PHS. Medical records of dogs diagnosed with primary PHS at 11 institutions were retrospectively reviewed. Thirty-seven dogs were included; 13 received CCNU-based chemotherapy alone, 18 received surgery and adjuvant CCNU-based chemotherapy, 3 received medical management alone and 3 dogs received surgery alone. The overall median progression free survival (PFS) and the median survival (overall survival [OS]) were 197 and 237 days, respectively. Measurable responses were noted in dogs receiving only chemotherapy; however, responses were not durable with PFS (91 days) and OS times (131 days) shorter than overall medians. Dogs that received surgery and chemotherapy had significantly prolonged PFS (276 days, P = 0.001) and OS (374 days, P = 0.001), compared with dogs not receiving surgery. As only three dogs undergoing surgery did not receive chemotherapy, it is not possible to determine the contribution of chemotherapy as an adjuvant to surgery. Dogs without evidence of intra-thoracic metastatic disease were much more likely to undergo surgery (odds ratio = 7.04; P = 0.018). While the presence of metastasis or clinical signs at diagnosis negatively impacted PFS, only the former negatively impacted OS. These data imply that dogs presenting with PHS amenable to surgery (ie, no clinical evidence of metastasis) benefit from surgical intervention; however, the lack of a comparable surgery alone group precludes assessment of the efficacy of post-surgical adjuvant chemotherapy.",
keywords = "dogs, histiocytic sarcoma, lung neoplasms, oncology",
author = "Marlowe, {Katelyn W.} and Robat, {Cecilia S.} and Clarke, {Dawn M.} and Angela Taylor and Maude Touret and Husbands, {Brian D} and Vail, {David M.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1111/vco.12437",
language = "English (US)",
volume = "16",
pages = "658--663",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Primary pulmonary histiocytic sarcoma in dogs

T2 - A retrospective analysis of 37 cases (2000-2015)

AU - Marlowe, Katelyn W.

AU - Robat, Cecilia S.

AU - Clarke, Dawn M.

AU - Taylor, Angela

AU - Touret, Maude

AU - Husbands, Brian D

AU - Vail, David M.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Primary pulmonary histiocytic sarcoma (PHS) has been reported, but is not well characterized. The aim of this retrospective study was to describe clinical characteristics, characterize prognostic factors and report the outcome of a larger group of dogs with primary PHS. Medical records of dogs diagnosed with primary PHS at 11 institutions were retrospectively reviewed. Thirty-seven dogs were included; 13 received CCNU-based chemotherapy alone, 18 received surgery and adjuvant CCNU-based chemotherapy, 3 received medical management alone and 3 dogs received surgery alone. The overall median progression free survival (PFS) and the median survival (overall survival [OS]) were 197 and 237 days, respectively. Measurable responses were noted in dogs receiving only chemotherapy; however, responses were not durable with PFS (91 days) and OS times (131 days) shorter than overall medians. Dogs that received surgery and chemotherapy had significantly prolonged PFS (276 days, P = 0.001) and OS (374 days, P = 0.001), compared with dogs not receiving surgery. As only three dogs undergoing surgery did not receive chemotherapy, it is not possible to determine the contribution of chemotherapy as an adjuvant to surgery. Dogs without evidence of intra-thoracic metastatic disease were much more likely to undergo surgery (odds ratio = 7.04; P = 0.018). While the presence of metastasis or clinical signs at diagnosis negatively impacted PFS, only the former negatively impacted OS. These data imply that dogs presenting with PHS amenable to surgery (ie, no clinical evidence of metastasis) benefit from surgical intervention; however, the lack of a comparable surgery alone group precludes assessment of the efficacy of post-surgical adjuvant chemotherapy.

AB - Primary pulmonary histiocytic sarcoma (PHS) has been reported, but is not well characterized. The aim of this retrospective study was to describe clinical characteristics, characterize prognostic factors and report the outcome of a larger group of dogs with primary PHS. Medical records of dogs diagnosed with primary PHS at 11 institutions were retrospectively reviewed. Thirty-seven dogs were included; 13 received CCNU-based chemotherapy alone, 18 received surgery and adjuvant CCNU-based chemotherapy, 3 received medical management alone and 3 dogs received surgery alone. The overall median progression free survival (PFS) and the median survival (overall survival [OS]) were 197 and 237 days, respectively. Measurable responses were noted in dogs receiving only chemotherapy; however, responses were not durable with PFS (91 days) and OS times (131 days) shorter than overall medians. Dogs that received surgery and chemotherapy had significantly prolonged PFS (276 days, P = 0.001) and OS (374 days, P = 0.001), compared with dogs not receiving surgery. As only three dogs undergoing surgery did not receive chemotherapy, it is not possible to determine the contribution of chemotherapy as an adjuvant to surgery. Dogs without evidence of intra-thoracic metastatic disease were much more likely to undergo surgery (odds ratio = 7.04; P = 0.018). While the presence of metastasis or clinical signs at diagnosis negatively impacted PFS, only the former negatively impacted OS. These data imply that dogs presenting with PHS amenable to surgery (ie, no clinical evidence of metastasis) benefit from surgical intervention; however, the lack of a comparable surgery alone group precludes assessment of the efficacy of post-surgical adjuvant chemotherapy.

KW - dogs

KW - histiocytic sarcoma

KW - lung neoplasms

KW - oncology

UR - http://www.scopus.com/inward/record.url?scp=85053723187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053723187&partnerID=8YFLogxK

U2 - 10.1111/vco.12437

DO - 10.1111/vco.12437

M3 - Article

VL - 16

SP - 658

EP - 663

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

IS - 4

ER -